Targeting dysregulated intracellular signaling pathways such as the AKT signaling pathway constitutes a promising future therapeutical strategy in bone metastasis of breast cancer, since AKT is frequently dysregulated in triple negative breast cancer and bone metastasis of breast cancer [8,27,29]. This evidence concerns the gene AKT1 and breast carcinoma.